MAO Xiao-yun, JIN Feng, WANG Kun. Phase Ⅲ Study of Bevacizumab plus Docetaxel Compared with Placebo plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 144-146. DOI: 10.3969/j.issn.1671-5144.2012.03.014
|
Citation:
|
MAO Xiao-yun, JIN Feng, WANG Kun. Phase Ⅲ Study of Bevacizumab plus Docetaxel Compared with Placebo plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 144-146. DOI: 10.3969/j.issn.1671-5144.2012.03.014
|
MAO Xiao-yun, JIN Feng, WANG Kun. Phase Ⅲ Study of Bevacizumab plus Docetaxel Compared with Placebo plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 144-146. DOI: 10.3969/j.issn.1671-5144.2012.03.014
|
Citation:
|
MAO Xiao-yun, JIN Feng, WANG Kun. Phase Ⅲ Study of Bevacizumab plus Docetaxel Compared with Placebo plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 144-146. DOI: 10.3969/j.issn.1671-5144.2012.03.014
|
DownLoad: